FDA Approves Eli Lilly Oral GLP-1 'Foundayo'

Eli Lilly's once-daily oral GLP-1 agonist orforglipron (brand name Foundayo) received FDA approval on April 1 and began distribution on April 6. In Phase 3 trials, the highest dose cohort achieved average weight loss of 12% over 72 weeks (vs. 0.9% for placebo) with no meal or timing restrictions. Pricing is set at $25/month for commercially insured patients and $149/month for self-pay; Medicare copay capped at $50 starting July 1.